Race Oncology (ASX: $RAC) announces appointment of George Clinical International for phase 1a/1b trial

Race Oncology Limited (RAC) has appointed George Clinical International to support the clinical development of RC220 bisantrene, a cardioprotective and anticancer treatment for solid tumour patients. The Phase 1a/1b trial will focus on cancer patients in Australia, Hong Kong, and South Korea with advanced solid tumours where doxorubicin treatment is indicated. This study aims to provide human safety and pharmacokinetic data, optimal dosing in combination with doxorubicin, and initial human data on the cardioprotective, anticancer, and m6A RNA activity of RC220 bisantrene.

Executive commentary on the appointment of George Clinical International

Race Chief Executive Officer, Dr Daniel Tillett, expressed, 'This agreement with George Clinical is a significant milestone for Race to bring RC220 bisantrene to the clinic to potentially protect patients from the heart damage caused by anthracyclines while improving the treatment of their cancer. I welcome the opportunity for Race to work with George Clinical and wish to thank the Race clinical team for their hard work and dedication in reaching this agreement.' Race Chief Medical Officer, Dr Michelle Rashford, added, 'This is a key foundational study to establish important safety and drug absorption kinetics for RC220 and provide appropriate doses for effective combination with doxorubicin to advance the development of RC220 for clinical cardiac benefit to patients treated with anthracyclines while providing improved outcomes. We are delighted George Clinical can support this significant step for Race and through the selection process their responsiveness and clinical insight has impressed us.'

Summary of Race Oncology's appointment of George Clinical International and outlook

Race Oncology's appointment of George Clinical International to support the clinical development of RC220 bisantrene marks a significant milestone in their efforts to bring potential cardioprotective and anticancer treatment to solid tumour patients. The Phase 1a/1b trial, focusing on advanced solid tumours in Australia, Hong Kong, and South Korea, aims to provide crucial human safety and pharmacokinetic data, optimal dosing in combination with doxorubicin, and initial human data on the cardioprotective, anticancer, and m6A RNA activity of RC220 bisantrene. The company anticipates the trial to complete recruitment during 2026. Furthermore, the trial's cost is expected to be well under $9 million, demonstrating clinical trial design efficiencies and careful CRO selection. Race Oncology's collaboration with George Clinical and the progress in the development of RC220 bisantrene reflect the company's commitment to addressing unmet needs of cancer patients and advancing potential treatments with improved outcomes.